deltatrials
Completed PHASE1 NCT00436657

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease

Sponsor: M.D. Anderson Cancer Center

Conditions Adenocarcinoma Adrenocortical Carcinoma Desmoplastic Small Round Cell Tumor Gastrointestinal Neoplasms Neuroblastoma Ovarian Neoplasms Peritoneal Neoplasms Retroperitoneal Neoplasms Rhabdomyosarcoma Sarcoma Wilms Tumor
Interventions Abdominal Surgery CHPP of Cisplatin
Updated 6 times since 2017 Last updated: Mar 29, 2012 Started: Feb 28, 2007 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

A PHASE1 clinical study on Adenocarcinoma and Adrenocortical Carcinoma, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States